<DOC>
	<DOCNO>NCT01119924</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy Safety Smilon® Depression Patients pain . Eligible patient randomly assign 1 2 arm , either Smilon® placebo , receive treatment 8 week study .</brief_summary>
	<brief_title>A Clinical Study Assessment Efficacy Safety Mirtazapine ( Smilon ) Depression Patients With Pain</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Male female Age 2065 year Diagnosis least one chronic pain syndrome diagnosis concomitant depression accord DSMIV criterion Have mean weekly pain score least 30 mm 100mm visual analog scale ( VAS ) ShortForm McGill Pain Questionnaire ( SFMPQ ) study entry Women child bear potential pregnant , breastfeed use effective contraceptive Known hypersensitivity Mirtazapine component Subjects clinically significant unstable medical psychiatric condition Subjects receive nerve block acupuncture pain relief</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Mirtazapine</keyword>
	<keyword>Smilon</keyword>
	<keyword>Depression</keyword>
	<keyword>Pain</keyword>
</DOC>